A Study Of PF-06647263 In Patients With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2017-05-10
Target enrollment:
Participant gender:
Summary
To assess the safety and tolerability at increasing dose levels of PF-06647263 in patients
with advanced solid tumors in order to determine the maximum tolerated dose and select the
recommended Phase 2 dose.